To evaluate the effectiveness of pramipexole treatment in patients with primary Restless Legs Syndrome (RLS) and, secondarily, the effect on work productivity impairment associated with RLS. METHODS: This was an open-label, 12 week-prospective, non-controlled, non-interventional trial in patients with primary moderate to severe RLS being treated with the non-ergot dopamine agonist pramipexole by general practitioners and internists across Germany under routine conditions. Work productivity impairment was assessed by the Work Productivity and Activity Impairment Questionnaire (WPAI), RLS severity was measured by the International RLS Study Group Rating Scale (IRLS). RESULTS: A total of 2,546 patients suffering from moderate to severe RLS were evaluated at 904 sites. The mean age of the patients was 64.8 years and 67.8% were female. Median treatment duration was 92 days. Patients were starting with a median initial pramipexole dose of 0.088 mg/d, were flexibly titrated and had a final maintenance dose of 0.35 mg/d. RLS severity was significantly improved: IRLS mean score was 25.7 at baseline and 9.6 at the final visit. From the total population 539 patients (21.2%) were in paid labour. The mean age of this sub-population was 52.1 years; 58.1% were female. Impairment while working due to RLS was reduced by 30% (median) in a subgroup of 436 patients, who reported impairment at baseline. In 162 patients reporting 'Missing from work due to health problems' at baseline, a 6.1 hours/week (mean) reduction at the final visit was assessed by the WPAI, which translates into an average reduction in productivity loss for working RLS patients of €1642 in Germany. CONCLUSION: Pramipexole showed to be highly effective in the treatment of RLS in routine care, as substantiated by IRLS. Work productivity was substantially increased and impairment while working due to RLS-symptoms was reduced in patients being in paid labour. 
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OSTEOPOROSIS-Clinical Outcomes Studies

METHODS:
Twelve randomized placebo controlled trials investigating the effects of zoledronic acid (1 study), alendronate (3), risedronate (2), ibandronate (1), etidronate (1), calcitonin (1), ralixofene (1), or strontium ranelate (2) in terms of fractures with a follow-up of 3 years (or 2 years if used for registration purposes) were identified with a systematic literature search. The endpoint of interest was morphometric vertebral fractures. Results of all trials were analyzed simultaneously with a Bayesian mixed treatment comparison (MTC). MTC is an extension of traditional meta-analysis by including multiple different pairwise comparisons across the range of different interventions. With MTC the relative treatment effect of one intervention to another can be obtained in the absence of head-to-head evidence. In contrast to a frequentist approach, a Bayesian analysis allows for direct probabilistic inferences. Outcomes were analyzed using a random effects model. RESULTS: There is a 73.6% probability that zoledronic acid shows the greatest reduction in vertebral fractures of all interventions compared, followed by etidronate (23.2% probability) and ibandronate (1.8%). Zoledronic acid showed an OR of 0.28 (95% Credible Interval 0.19-0.40) relative to placebo, an OR of 0.62 relative to etidronate, and an OR of 0.55 relative to ibandronate. Corresponding probabilities that zoledronic provides a greater vertebral risk reduction are 99.9%, 79.6%, and 98.9% compared to placebo, etidronate, and ibandronate, respectively. Similar comparisons are under investigation for other fracture endpoints. CONCLUSION: Of the available treatments for osteoporosis, zoledronic acid is one of the treatments that provide greatest fracture risk reductions in general. Furthermore zoledronic acid showed greatest reductions regarding vertebral fractures. Regarding intracapsular femoral neck fractures, the main focus of research is the correlation between fracturerelated complications and prognostic factors. The purpose of this study was to evaluate the correlation between complications required surgery (fracture-related treatment) and, among others, several less extensively investigated prognostic factors (day of surgery, co-morbidities, hospital type) in a 2-year period following internal fixation in young adults with intracapsular femoral neck fracture. METHODS: Retrospective analysis of femoral neck fractures occurred in Hungary in 2000, based on data obtained from the National Health Fund Administration. The data were validated and completed by a questionnaire carried out Abstracts A393
POS2 CORRELATION BETWEEN PREDICTORS AND SUBSEQUENT SURGICAL MANAGEMENT FOLLOWING INTERNAL FIXATION OF FEMORAL NECK FRACTURES
